238
Participants
Start Date
May 31, 2006
Primary Completion Date
July 31, 2007
Study Completion Date
July 31, 2007
Placebo
Corresponding placebo is applied for 12weeks
Buprenorphine Transdermal System
Buprenorphine Transdermal System 5, 10 or 20 mg/patch is applied for 12weeks
Investigational Site, Ichikawa
Investigational Site, Matsudo
Investigational Site, Noda
Investigational Site, Asakura
Investigational Site, Fukuoka
Investigational Site, Wakasugi
Investigational Site, Takasaki
Investigational Site, Sapporo
Investigational Site, Kobe
Investigational Site, Yūki
Investigational Site, Kanazawa
Investigational Site, Komatsu
Investigational Site, Hanamaki
Investigational Site, Morioka
Investigational Site, Yokohama
Investigational Site, Sendai
Investigational Site, Niigata
Investigational Site, Osaka
Investigational Site, Yao
Investigational Site, Koshigaya
Investigational Site, Tokorozawa
Investigational Site, Hikone
Investigational Site, Adachi City
Investigational Site, Arakawa City
Investigational Site, Edogawa City
Investigational Site, Ōta-ku
Investigational Site, Suginami
Investigational Site, tabashi City
Investigational Site, Toshima City
Lead Sponsor
Mundipharma K.K.
INDUSTRY